Nøkkelinformasjon info chevron_right

Viktig informasjon i saken hentes i sanntid direkte fra EPO sitt register (European Patent Register), slik at du enkelt og raskt får oversikt i saken.
Beskrivelse Verdi
Saken / databasen er sist oppdatert info  
Tittel 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES
Status
Hovedstatus
Detaljstatus 		Ikke i kraft info Patent opphørt Ikke betalt årsavgift
Patentnummer NO/EP3177619
Europeisk (EP) publiserings nummer EP3177619
EP levert
EP søknadsnummer 15744596.6
EP meddelt
Avdelt til EP3395818;
Prioritet 2014.08.04, EP 14179692, .... se mer/flere nedenfor
Sakstype Europeisk
Løpedag
Utløpsdato
Allment tilgjengelig
Validert i Norge
Innehaver Bayer Pharma Aktiengesellschaft (DE)
Oppfinner WORTMANN, Lars (DE) .... se mer/flere nedenfor
Fullmektig ZACCO NORWAY AS (NO)
Lenke til European patent Register Informasjon i saken, dokumenter og patentfamilie
Patentfamilie Se i Espacenet

Sammendrag og figur info chevron_right

EPO translation logo


Se forsidefigur og sammendrag i Espacenet

Beskrivelse og krav info chevron_right

T3

Beskrivelse

Krav

Patentkrav1. Forbindelse med generell formel der:R1 representerer en gruppe valgt fra:hvori * representerer festepunktet for gruppen til resten av molekylet;R2 representerer hydrogen, halogen, -NR7R8, CN, C1-C6-alkyl, C1-C6-alkoksy, 3- til 10-leddet heterosykloalkoksy, C2-C6-alkenyl, C3-C6-sykloalkyl, 3- til 10-leddet heterosykloalkyl, 4- til 10-leddet heterosykloalkenyl, fenyl, heteroaryl, -(CO)OR7, -(CO)NR7R8, -(SO2)R9, -(SO)R9, -SR9, -(SO2)NR7R8, -NR7(SO2)R9, -((SO)=NR11)R10, -N=(SO)R9R10, -SiR10R11R12, -(PO)(OR7)2, -(PO)(OR7)R10 eller -(PO)(R10)2,hvori hvert C1-C6-alkyl, C1-C6-alkoksy, 3- til 10-leddet heterosykloalkoksy, C2-C6-alkenyl, C3-C6-sykloalkyl, 3- til 10-leddet heterosykloalkyl, fenyl eller heteroaryl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med halogen, OH, -NR7R8, C1-C6-alkyl eventuelt substituert med hydroksyl eller fenyl, C1-C6-halogenalkyl, C1-C6-alkoksy, C3-C6-sykloalkyl, 3- til 6-leddet heterosykloalkyl, fenyl,-(CO)OR7, -(CO)NR7R8, -NR7(CO)R10, NR8(CO)OR7, -NR8(CO)NR7R8, -(SO2)R9, -(SO)R9, -SR9,-(SO2)NR7R8, -NR7(SO2)R9, -((SO)=NR11)R10, -N=(SO)R9R10, -(PO)(OR7)2, -(PO)(OR7)R10, -(PO)(R10)2 eller med en heteroarylgruppe som eventuelt er substituert, én eller flere ganger, med C1-C4-alkyl;hvori hvert 4- til 10-leddede heterosykloalkenyl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med C1-C4-alkyl;R3, R4 representerer, uavhengig av hverandre, hydrogen eller metyl;R7, R8 representerer, uavhengig av hverandre, hydrogen, C1-C6-alkyl, C3-C6-sykloalkyl eller fenyl, idet fenylet eventuelt er substituert én eller flere ganger, med halogen; eller R7 og R8 sammen representerer en 4-, 5-, 6- eller 7-leddet syklisk amingruppe, som eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med en substituent valgt fra C1-C6-alkyl, C1-C6-halogenalkyl, den 4-, 5-, 6- eller 7-leddede sykliske amingruppen som eventuelt inneholder ett ytterligere heteroatom valgt fra gruppen som består av O, N og S;R9 representerer C1-C4-alkyl eller fenyl, hvori hvert C1-C4-alkyl eller fenyl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med R13;R10 representerer C1-C4-alkyl; ellerR9 og R10 sammen, i tilfellet av -N=(SO)R9R10-gruppe, representerer en 5- til 8-leddet heterosykloalkylgruppe;R11 representerer hydrogen, C1-C4-alkyl, -(CO)OR7, -(CO)NR7R8 eller CN;R12 representerer hydrogen eller C1-C4-alkyl;R13 representerer halogen, OH, -NR7R8, CN, NO2, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoksy, C1-C6-halogenalkoksy, C2-C6-alkenyl, C3-C6-sykloalkyl, -(CO)OR7 eller -(CO)NR7R8;eller en stereoisomer, en tautomer, et N-oksid, et hydrat, et solvat eller et salt derav eller en blanding av det samme.2. Forbindelsen ifølge krav 1, derR1 representerer en gruppe valgt fra:hvori * indikerer festepunktet for gruppen med resten av molekylet;R2 representerer hydrogen, halogen, -NR7R8, CN, C1-C6-alkyl, C1-C6-alkoksy, 3- til 10-leddet heterosykloalkoksy, C2-C6-alkenyl, C3-C6-sykloalkyl, 3- til 10-leddet heterosykloalkyl, 4- til 10-leddet heterosykloalkenyl, fenyl, heteroaryl, -(CO)OR7, -(CO)NR7R8, -(SO2)R9, -(SO)R9, -SR9, -(SO2)NR7R8, -NR7(SO2)R9, -((SO)=NR11)R10, -N=(SO)R9R10, -SiR10R11R12, -(PO)(OR7)2, -(PO)(OR7)R10 eller -(PO)(R10)2,hvori hvert C1-C6-alkyl, C1-C6-alkoksy, 3- til 10-leddet heterosykloalkoksy, C2-C6-alkenyl, C3-C6-sykloalkyl, 3- til 10-leddet heterosykloalkyl, fenyl eller heteroaryl eventuelt er substituert, én eller flere ganger, uavhengig fra hverandre, med halogen, OH, -NR7R8, C1-C6-alkyl, 3- til 6-leddet heterosykloalkyl, 4- til 6-leddet heterosykloalkenyl fenyl, -(CO)OR7, -(CO)NR7R8, -NR7(CO)R10,-NR8(CO)OR7, -NR8(CO)NR7R8, -(SO2)R9, -(SO)R9, -SR9, -(SO2)NR7R8, -NR7(SO2)R9, -((SO)=NR11)R10, -N=(SO)R9R10, -(PO)(OR7)2,-(PO)(OR7)R10, -(PO)(R10)2 eller med en heteroarylgruppe som eventuelt er substituert, én eller flere ganger, med C1-C4-alkyl; hvori hvert 4- til 10-leddede heterosykloalkenyl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med C1-C4-alkyl;R3, R4 representerer, uavhengig av hverandre, hydrogen eller metyl; R7, R8 representerer, uavhengig av hverandre, hydrogen eller C1-C6-alkyl; ellerR7 og R8 sammen representerer en 4-, 5-, 6- eller 7-leddet syklisk amingruppe, som eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med en substituent valgt fra C1-C6-alkyl, C1-C6-halogenalkyl, den 4-, 5-, 6- eller 7-leddede sykliske amingruppen som eventuelt inneholder ett ytterligere heteroatom valgt fra gruppen som består av O, N og S;R9 representerer C1-C4-alkyl eller fenyl, hvori hvert C1-C4-alkyl eller fenyl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med R13;R10 representerer C1-C4-alkyl; ellerR9 og R10 sammen, i tilfellet av -N=(SO)R9R10-gruppe, representerer en 5- til 8-leddet heterosykloalkylgruppe;R11 representerer hydrogen, C1-C4-alkyl, -(CO)OR7, -(CO)NR7R8 eller CN;R12 representerer hydrogen eller C1-C4-alkyl;R13 representerer halogen, OH, -NR7R8, CN, NO2, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoksy, C1-C6-halogenalkoksy, C2-C6-alkenyl, C3-C6-sykloalkyl, -(CO)OR7 eller -(CO)NR7R8.3. Forbindelsen ifølge krav 1, som er valgt fra gruppen:4-[(2-(morfolin-4-yl)-8-[2H-pyrazol-3-yl]-[1,7]naftyridin-4-yl]fenyl-N-etoksykarbonyl-S-metylsulfoksimid4-[(2-(morfolin-4-yl)-8-(2H-pyrazol-3-yl)-[1,7]naftyridin-4-yl]fenyl-S-metylsulfoksimid 4-[6-(metylsulfonyl)pyridin-3-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(3,6-dihydro-2H-pyran-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin 4-[4-(N,S-dimetylsulfonimidoyl)fenyl]-2-[morfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[4-metyl-6-(metylsulfonyl)pyridin-3-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(4-metansulfonylfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]-naftyridin4-(2-metansulfonylfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin hydrokloriddimetyl {4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenyl}fosfonat 4-isopropenyl-2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin2-(morfolin-4-yl)-4-fenyl-8-(1H-pyrazol-3-yl)-[1,7]naftyridin4-[4-(S-etylsulfonimidoyl)fenyl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 3-[(2-(morfolin-4-yl)-8-[2H-pyrazol-3-yl]-[1,7]naftyridin-4-yl]fenyl-N-etoksykarbonyl-S-metylsulfoksimid4-(1-metyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(3-metansulfonylfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin4-[5-metyl-6-(metylsulfonyl)pyridin-3-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(1,2,3,6-tetrahydropyridin-4-yl)-1,7-naftyridin 4-syklopropyl-2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin3-[(2-(morfolin-4-yl)-8-(2H-pyrazol-3-yl)-[1,7]naftyridin-4-yl]fenyl-S-metylsulfoksimid 4-metyl-2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridinhydroklorid4-[2-(metylsulfonyl)-1,3-tiazol-4-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]pyridin-2(1H)-on5-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]pyridin-2(1H)-on4-[2-fluor-4-(metylsulfonyl)fenyl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-(morfolin-4-yl)-4-{4-[S-(propan-2-yl)sulfonimidoyl]fenyl}-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(4-metansulfonylfenyl)-2-((R)-3-metylmorfolin-4-yl)-8-(2H-pyrazol-3-yl)-[1,7]naftyridin2-((R)-3-metylmorfolin-4-yl)-4-fenyl-8-(2H-pyrazol-3-yl)-[1,7]naftyridin4-(3-metansulfonylfenyl)-2-((R)-3-metylmorfolin-4-yl)-8-(2H-pyrazol-3-yl)-[1,7]naftyridin4-syklopropyl-2-((R)-3-metylmorfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]-naftyridin4-[2-((R)-3-metylmorfolin-4-yl)-8-(2H-pyrazol-3-yl)-[1,7]naftyridin-4-yl]fenyl-S-metylsulfoksimid3-[2-((R)-3-metylmorfolin-4-yl)-8-(2H-pyrazol-3-yl)-[1,7]naftyridin-4-yl]fenyl-S-metylsulfoksimid4-metansulfonyl-2-(morfolin-4-yl)-8-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]-[1,7]naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(metylsulfonyl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin-4-karbonitril2-((R)-3-metylmorfolin-4-yl)-8-(-2H-pyrazol-3-yl]-[1,7]naftyridin-4-karbonitril2-morfolin-4-yl-8-(1H-pyrazol-3-yl)-[1,7]naftyridin-4-karboksamid4-metansulfonylmetyl-2-morfolin-4-yl-8-(2H-pyrazol-3-yl)-[1,7]naftyridin[2-(morfolin-4-yl)-8-(2H-pyrazol-3-yl)-[1,7]naftyridin-4-yl]metanol4-(1-metansulfonylsyklopropyl)-2-(morfolin-4-yl)-8-(2H-pyrazol-3-yl)-[1,7]naftyridin 4-isopropoksy-2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin2-(morfolin-4-yl)-4-(propan-2-yloksy)-8-(1H-pyrrol-2-yl)-1,7-naftyridin4-[3-(S-metylsulfonimidoyl)propoksy]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-etoksy-2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin4-metoksy-2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin 2-metyl-1-{[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]oksy}propan-2-ol 2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(tetrahydrofuran-2-ylmetoksy)-1,7-naftyridin 3-{[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]oksy}dihydrofuran-2(3H)-on4-[(3-metyl-1,2-oksazol-5-yl)metoksy]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[(5-metyl-1,2-oksazol-3-yl)metoksy]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-benzyloksy-2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin4-isopropoksy-2-((R)-3-metylmorfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin tert-butyl [4-({2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}oksy)butyl]karbamat4-metoksy-2-((R)-3-metylmorfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridintert-butyl [3-({2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}oksy)propyl]karbamat2-({2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}oksy)etanamintert-butyl [2-({2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}oksy)etyl]karbamat4-({2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}oksy)butan-1-amin2-[(3R,5S)-3,5-dimetylmorfolin-4-yl]-4-isopropoksy-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R,5R)-3,5-dimetylmorfolin-4-yl]-4-isopropoksy-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(tetrahydro-2H-pyran-4-yl)-1,7-naftyridin 2-(morfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridinhydroklorid4-klor-2-morfolin-4-yl-8-(1H-pyrazol-3-yl)-[1,7]naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(metylsulfanyl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin N-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}-1,4λ4-oksatian-4-imin-4-oksid4-{[dimetyl(oksido)-λ6-sulfanyliden]amino}-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(piperazin-1-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-isopropoksy-2-((S)-3-metylmorfolin-4-yl)-8-(1H-pyrazol-3-yl)-[1,7]naftyridin2-(morfolin-4-yl)-4-(propan-2-yloksy)-8-(1H-pyrrol-3-yl)-1,7-naftyridin4-(1-etyl-1H-pyrazol-5-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1-metyl-1H-imidazol-5-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]anilin4-(2,3-difluorfenyl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-[2-metyl-6-(metylsulfonyl)pyridin-3-yl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[2-fluor-4-(metylsulfonyl)fenyl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-fluor-2-[2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]anilin 4-(1-benzyl-1H-imidazol-5-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2-fluorfenyl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-4-(2-metyl-1,3-tiazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[4-metyl-6-(metylsulfonyl)pyridin-3-yl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1-syklopropyl-1H-pyrazol-5-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[2-fluor-4-(piperazin-1-yl)fenyl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-[4-(metylsulfonyl)piperazin-1-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridinN-(2,2-dimetylpropyl)-N-metyl-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin(1-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}piperidin-4-yl)metanolN-syklopropyl-N-metyl-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin4-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridinN-(4-fluorfenyl)-N-metyl-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin2-[(3R)-3-metylmorfolin-4-yl]-4-(6-metylpyridin-3-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(2-fluorpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(2-fluor-4-metylpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(1-metyl-1H-pyrrol-2-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(6-fluor-5-metylpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(2-fluor-6-metylpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(6-fluorpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(6-metoksypyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(6-metoksy-5-metylpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(6-fluor-2-metylpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-[1-metyl-3-(trifluormetyl)-1H-pyrazol-5-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(3-metyl-2-tienyl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-4-(5-metyl-2-tienyl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-4-(4-metyl-3-tienyl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(3-klor-2-tienyl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-4-(2-metyl-3-tienyl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1,7-naftyridin4-(3,5-dimetyl-1,2-oksazol-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(3-klor-2-metoksypyridin-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-4-(tetrahydro-2H-pyran-4-yl)-1,7-naftyridin4-(3,6-dihydro-2H-tiopyran-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(4-metylpiperidin-1-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1-tert-butyl-1H-pyrazol-5-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(1-metyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(3-metyl-1,2-oksazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1-etyl-3-metyl-1H-pyrazol-5-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1,4-dimetyl-1H-pyrazol-5-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-[2-metyl-6-(metylsulfanyl)pyridin-3-yl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[2-metyl-6-(S-metylsulfonimidoyl)pyridin-3-yl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(1-propyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[1-etyl-3-(trifluormetyl)-1H-pyrazol-5-yl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridinmetyl-5-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}-1H-pyrrole-2-karboksylat2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-4-(1,2-tiazol-5-yl)-1,7-naftyridin N,N-dimetyl-2-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}anilin4-(2,4-difluorfenyl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(1-isopropyl-1H-pyrazol-5-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridinetylmetyl{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}fosfinat 4-{[dietyl(oksido)-λ6-sulfanyliden]amino}-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridinisobutyl metyl{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}fosfinat2-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}propan-2-ol 3-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}pentan-3-ol 4-(5-klorpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 5-fluor-2-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}anilin 4-[2-fluor-3-(metylsulfonyl)fenyl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-[1-(oksetan-3-yl)-1H-pyrazol-5-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[2-fluor-4-(pyrrolidin-1-yl)fenyl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[3-(metoksymetyl)-5-metyl-1,2-oksazol-4-yl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(5-metyl-1,3,4-oksadiazol-2-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin N-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}tetrahydro-1H-1λ4-tiofen-1-imin-1-oksid4-{[(4-fluorfenyl)(metyl)oksido-λ6-sulfanyliden]amino}-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin, blanding av 2-diastereoisomerer4-{[(2-fluorfenyl)(metyl)oksido-λ6-sulfanyliden]amino}-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin, blanding av 2-diastereoisomerer4-{[(R)(2-fluorfenyl)(metyl)oksido-λ6-sulfanyliden]amino}-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin, diastereoisomer4-{[(S)(2-fluorfenyl)(metyl)oksido-λ6-sulfanyliden]amino}-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin, diastereoisomer4-(dimetylfosforyl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(dietylfosforyl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin etylisobutyl{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}fosfinat2-[(3R)-3-metylmorfolin-4-yl]-4-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(1-isobutyl-1H-pyrazol-5-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[5-fluor-6-(metylsulfonyl)pyridin-3-yl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[(3R)-3-metylmorfolin-4-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-4-(4-metyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[2-fluor-5-(metylsulfonyl)fenyl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[4-(isopropylsulfonyl)fenyl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(6-fluorpyridin-2-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(1-etyl-1H-imidazol-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin1-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}prolinamid 3-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}pyridin-2-amin 2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-4-[1-(2,2,2-trifluoretyl)-1H-pyrazol-5-yl]-1,7-naftyridin1-metyl-4-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}piperazin-2-on4-[1-(2-fluoretyl)-1H-pyrazol-3-yl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-[1-(2-fluoretyl)-1H-pyrazol-5-yl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(3-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}-1H-pyrazol-1-yl)etanol2-metyl-1-(3-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}-1H-pyrazol-1-yl)propan-2-ol4-[(2R)-2-metylmorfolin-4-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(5-fluorpyridin-2-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-4-(6-metylpyridin-2-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-4-(3-metylpyridin-2-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin N-(2-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}fenyl)acetamid3-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}pyridin-2-ol 2-(3-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}fenyl)propan-2-ol4-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[(2S)-2-metylmorfolin-4-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-[(trans)-2-metylsyklopropyl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(difluormetoksy)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]propan-2-ol2-(morfolin-4-yl)-4-(3-oksa-8-azabisyklo[3.2.1]okt-8-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-4-(pyrrolidin-1-yl)-1,7-naftyridin 4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]piperazin-2-on4-(dimetylfosforyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[(trans)-2,5-dimetylpiperazin-1-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[(cis)-3,5-dimetylpiperazin-1-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 1-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]-3-(trifluormetyl)azetidin-3-olMetylhydrogen-{4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenyl}fosfonat4-(4-metylpiperazin-1-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-[(3aR,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl]-1,7-naftyridin4-(3-metoksy-3-metylazetidin-1-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-(morfolin-4-yl)-4-[(1S,4S)-2-oksa-5-azabisyklo[2.2.1]hept-5-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-[(metylsulfanyl)metyl]-8-(1H-pyrazol-5-yl)-1,7-naftyridinN,N-dimetyl-5-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]pyridin-2-amin 4-(2-metylpyridin-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin1-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}sykloheksanol 2-fluor-6-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}anilin (metyl{4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenyl}oksido-λ6-sulfanyliden)cyanamid1-etyl-3-(metyl{4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenyl}oksido-λ6-sulfanyliden)urea3-({2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}oksy)propan-1-amin4-(4-syklopropyl-1H-1,2,3-triazol-5-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-etylsulfinyl-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-4-[propan-2-ylsulfinyl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-[3-(metylsulfonyl)propoksy]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-4-(fenylsulfonyl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-4-(propan-2-ylsulfonyl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(etylsulfonyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-4-(fenylsulfinyl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(metylsulfinyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-[1-oksidotetrahydro-2H-tiopyran-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1,1-dioksidotetrahydro-2H-tiopyran-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4,8-di(1H-pyrazol-5-yl)-1,7-naftyridinN,N-dimetyl-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin2-(morfolin-4-yl)-4-(fenylsulfanyl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-N-(propan-2-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin4-(etylsulfanyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-4-(propan-2-ylsulfanyl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(1H-pyrrol-2-yl)-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(1H-pyrrol-3-yl)-1,7-naftyridin4-[(4-metoksyfenyl)sulfanyl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(5-metyl-1H-pyrazol-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 1-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]pyrrolidin-2-on4-(1,1-dioksido-1,2-tiazolidin-2-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 1-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]piperidin-2-on2-[(3R)-3-metylmorfolin-4-yl]-4-(2-metylpyridin-3-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-4-[2-(propan-2-yloksy)pyridin-3-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2-metoksypyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(pyridin-4-yl)-1,7-naftyridin4-[(4-metoksyfenyl)sulfanyl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[3-fluor-2-(morfolin-4-yl)pyridin-4-yl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(6-fluor-5-metylpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]-1,3-oksazinan-2-on 3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]-1,3-oksazolidin-2-on 4-(3-metoksypyridin-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2,6-difluorpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(5-klor-2-fluorpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(3-fluorpyridin-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(2-klor-6-metylpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(5,6-dimetylpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(5-fluor-6-metylpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(5-metyltiofen-3-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(3-metoksytiofen-2-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2-klortiofen-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(isokinolin-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(5-klortiofen-2-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-4-(4-metyltiofen-2-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(2,5-dimetyltiofen-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-4-(tetrahydro-2H-tiopyran-4-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(1-metyl-1,2,5,6-tetrahydropyridin-3-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(1-metyl-1,2,3,6-tetrahydropyridin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-[1-metylpiperidin-3-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-4-(1,2,3,6-tetrahydropyridin-4-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-4-[1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl]-1,7-naftyridin4-(4,6-difluorpyridin-3-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(1-metyl-1H-pyrazol-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1,3-dimetyl-1H-pyrazol-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1,5-dimetyl-1H-pyrazol-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(piperidin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-4-[3-(trifluormetyl)-1H-pyrazol-4-yl]-1,7-naftyridin4-(1-syklobutyl-1H-pyrazol-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1-syklopropyl-1H-pyrazol-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-[1-(propan-2-yl)-1H-pyrazol-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[1-(difluormetyl)-1H-pyrazol-4-yl]-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1-tert-butyl-1H-pyrazol-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-4-(1,3,5-trimetyl-1H-pyrazol-4-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-4-[1-metyl-3-(trifluormetyl)-1H-pyrazol-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(4-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}-1H-pyrazol-1-yl)etanol4-(1-etyl-1H-pyrazol-4-yl)-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(1-metyl-1H-pyrrol-3-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-[1-(propan-2-yl)-1H-pyrazol-3-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-4-(1,2,5-trimetyl-1H-pyrrol-3-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(1-fenyl-1H-pyrazol-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(3-metyl-1H-pyrazol-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin2-[(3R)-3-metylmorfolin-4-yl]-4-[1-(2-metylpropyl)-1H-pyrazol-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[(3R)-3-metylmorfolin-4-yl]-4-(1H-pyrazol-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-[(3R)-3-metylmorfolin-4-yl]-4-(1,3-oksazol-2-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(1,3-dimetyl-1H-pyrazol-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(1,5-dimetyl-1H-pyrazol-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(1,3,5-trimetyl-1H-pyrazol-4-yl)-1,7-naftyridin 4-{[(2-metoksyetyl)(metyl)oksido-λ6-sulfanyliden]amino}-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-{[(4-bromfenyl)(oksido)propan-2-yl-λ6-sulfanyliden]amino}-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(metyl-N-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}sulfonimidoyl)fenol4-{[(4-bromfenyl)(metyl)oksido-λ6-sulfanyliden]amino}-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-{[tert-butyl(metyl)oksido-λ6-sulfanyliden]amino}-2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridinmaursyre-N-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]-1,4λ4-oksatian-4-imin-4-oksid (1:1)N-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]heksahydro-1λ4-tiopyran-1-imin-1-oksid 3-metyl-2-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}butan-2-ol1-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}-1-(tetrahydro-2H-pyran-4-yl)etanol3,3-dimetyl-2-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}butan-2-ol2-{2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl}heksan-2-ol 2-[(3R)-3-metylmorfolin-4-yl]-8-(1H-pyrazol-3-yl)-1,7-naftyridin-4-karboksamid2-[(3R)-3-metylmorfolin-4-yl]-4-[1-(metylsulfonyl)syklopropyl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(tetrahydro-2H-pyran-4-ylmetoksy)-1,7-naftyridinN,N-dimetyl-3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]benzamid {4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenyl}(piperidin-1-yl)metanonN,N-dimetyl-2-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]benzamid N-syklopropyl-4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]benzamid 4-(4-metylpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1H-indol-6-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1H-indol-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]benzamid4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]benzamidN-metyl-3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]benzamid4-(3-fluorfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(5-klortiofen-2-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2-metoksyfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-[2-(trifluormetyl)fenyl]-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-[4-(trifluormetyl)fenyl]-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-[3-(trifluormetyl)fenyl]-1,7-naftyridin4-(3-klorfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridinN-{3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenyl}acetamid4-(3-metoksyfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(3,5-dimetoksyfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(3-metylfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(4-metoksyfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(furan-2-ylmetyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2,6-dimetyl-4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenol4-(2,3-dimetylfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin {3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenyl}metanol4-(4-fluorfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(4-metylfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(4-klorfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2-fluor-3-metoksyfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(2-metylfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2,3-dimetoksyfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridinN,N-dimetyl-3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]anilin N,N-dimetyl-2-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]anilinN-{2-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenyl}metansulfonamid N-{4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenyl}metansulfonamid N,N-dimetyl-4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]benzamid 2-(morfolin-4-yl)-4-[(1E)-prop-1-en-1-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenol4-(2-fluorfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin{3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenyl}(piperidin-1-yl)metanon2-(morfolin-4-yl)-4-[4-(propan-2-yl)fenyl]-8-(1H-pyrazol-5-yl)-1,7-naftyridinN-syklopropyl-3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]benzamid 4-(bifenyl-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2,4-dimetoksyfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2-klorfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2,5-dimetylfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]anilin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-[3-(1H-pyrazol-1-yl)fenyl]-1,7-naftyridin 3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]fenol4-(2-fluor-5-metoksyfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(5-fluor-2-metoksyfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(2,4-difluorfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2,3-difluorfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2,6-dimetoksyfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]anilin4-(3,5-diklorfenyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(bifenyl-2-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2-klorpyridin-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1-benzotiofen-2-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1-metyl-1H-pyrazol-5-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(kinolin-5-yl)-1,7-naftyridin 2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(pyridin-3-yl)-1,7-naftyridin4-(2-metoksypyridin-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(5-metylpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(5-metoksypyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(kinolin-3-yl)-1,7-naftyridin2-(morfolin-4-yl)-4-[1-(fenylsulfonyl)-1H-indol-2-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(2-klorpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(6-klorpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin{5-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]tiofen-2-yl}metanol 4-(2-fluorpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(6-fluorpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2-klor-6-metylpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(2-metoksypyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(isokinolin-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(3-klorpyridin-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(3-fluorpyridin-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2,6-difluorpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1-metyl-1H-pyrazol-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin tert-butyl 5-metoksy-2-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]-1H-indol-1-karboksylat2-(morfolin-4-yl)-4-[6-(morfolin-4-yl)pyridin-3-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(4-metyltiofen-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(tiofen-2-yl)-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(tiofen-3-yl)-1,7-naftyridin4-(3-metyltiofen-2-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2-klor-5-metylpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(4-metoksypyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(5-klor-2-metoksypyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin tert-butyl 5-metyl-2-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]-1H-indol-1-karboksylat4-(5-klor-2-fluorpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(3,5-dimetyl-1,2-oksazol-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(kinolin-8-yl)-1,7-naftyridin4-(5-metyltiofen-2-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(6-etoksypyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(2-etoksypyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(kinolin-6-yl)-1,7-naftyridin4-(2-klortiofen-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 5-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]pyridin-2-amin 2-(morfolin-4-yl)-4-(1H-pyrazol-3-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(6-metylpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(1-metyl-1H-pyrrol-2-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin5-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]pyridin-2-ol4-(5-klorpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(3-klor-2-metoksypyridin-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(3-klortiofen-2-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(5-fluorpyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-[2-(metylsulfanyl)pyrimidin-5-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin N-syklopropyl-5-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]pyrimidin-2-amin4-(isokinolin-5-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridinN-metyl-5-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]pyridin-2-karboksamidN-tert-butyl-5-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]pyridin-3-karboksamid4-[5-(metylsulfanyl)pyridin-3-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1,7-naftyridin 3-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]pyridin-2-aminMetyl-4-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]tiofen-2-karboksylat 4-[2-metoksy-5-(trifluormetyl)pyridin-3-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin2-(morfolin-4-yl)-4-[2-(propan-2-yloksy)pyridin-3-yl]-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(5-klor-6-etoksypyridin-3-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(1-tert-butyl-1H-pyrazol-4-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-(morfolin-4-yl)-4-(piperidin-1-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin1-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]piperidin-4-olN-metyl-2-(morfolin-4-yl)-N-fenyl-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin{1-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]pyrrolidin-2-yl}metanol N-metyl-2-(morfolin-4-yl)-N-propyl-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin4-(azepan-1-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(3-metylpiperidin-1-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(4-metylpiperidin-1-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin1-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]piperidin-3-karboksamid 4-(2,5-dihydro-1H-pyrrol-1-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(3,4-dihydrokinolin-1(2H)-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(3,4-dihydroisokinolin-2(1H)-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-(1,3-dihydro-2H-isoindol-2-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-4-[1,3,3-trimetyl-6-azabisyklo[3.2.1]okt-6-yl]-1,7-naftyridintert-butyl1-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]-prolinatN-metyl-N-(2-metylpropyl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin N-(3-fluorfenyl)-N-metyl-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin 4-(1,1-dioksido-1-tia-6-azaspiro[3.3]hept-6-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin4-(3-fluorpiperidin-1-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridinN-(2-fluorfenyl)-N-metyl-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin 1-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]-prolinamid{1-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]piperidin-4-yl}metanol 4-(4-metoksypiperidin-1-yl)-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridinN-(4-fluorfenyl)-N-metyl-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin N-metyl-1-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]-prolinamid4-[4-(etylsulfonyl)piperazin-1-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin 4-[4-(metylsulfonyl)piperazin-1-yl]-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin N-syklopropyl-N-metyl-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin N-(2,2-dimetylpropyl)-N-metyl-2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-amin{1-[2-(morfolin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin-4-yl]piperidin-3-yl}metanol4. Forbindelsen ifølge kravene 1 eller 2 med generell formel (Ib)derR1 representerer:hvori * indikerer festepunktet for gruppen med resten av molekylet;R2 representerer hydrogen, halogen, -NR7R8, CN, C1-C6-alkyl, C1-C6-alkoksy, 3- til 10-leddet heterosykloalkoksy, C2-C6-alkenyl, C3-C6-sykloalkyl, 3- til 10-leddet heterosykloalkyl, 4- til 10-leddet heterosykloalkenyl, fenyl, heteroaryl, -(CO)OR7, -(CO)NR7R8, -(SO2)R9, -(SO)R9, -SR9, -(SO2)NR7R8, -NR7(SO2)R9, -((SO)=NR11)R10, -N=(SO)R9R10, -SiR10R11R12, -(PO)(OR7)2, -(PO)(OR7)R10 eller -(PO)(R10)2,hvori hvert C1-C6-alkyl, C1-C6-alkoksy, 3- til 10-leddet heterosykloalkoksy, C2-C6-alkenyl, C3-C6-sykloalkyl, 3- til 10-leddet heterosykloalkyl, fenyl eller heteroaryl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med halogen, OH, -NR7R8, C1-C6-alkyl eventuelt substituert med hydroksyl eller fenyl, C1-C6-halogenalkyl,C1-C6-alkoksy, C3-C6-sykloalkyl, 3- til 6-leddet heterosykloalkyl, fenyl, -(CO)OR7, -(CO)NR7R8, -NR7(CO)R10, NR8(CO)OR7, -NR8(CO)NR7R8, -(SO2)R9, -(SO)R9, -SR9, -(SO2)NR7R8, -NR7(SO2)R9, -((SO)=NR11)R10, -N=(SO)R9R10, -(PO)(OR7)2, -(PO)(OR7)R10, -(PO)(R10)2 eller med en heteroarylgruppe som eventuelt er substituert, én eller ganger, med C1-C4-alkyl;hvori hvert 4- til 10-leddede heterosykloalkenyl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med C1-C4-alkyl;R3, R4 representerer, uavhengig av hverandre, hydrogen eller metyl;R7, R8 representerer, uavhengig av hverandre, hydrogen, C1-C6-alkyl, C3-C6-sykloalkyl eller fenyl, idet fenylet eventuelt er substituert én eller flere ganger, med halogen; eller R7 og R8 sammen representerer en 4-, 5-, 6- eller 7-leddet syklisk amingruppe, som eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med en substituent valgt fra C1-C6-alkyl, C1-C6-halogenalkyl, den 4-, 5-, 6- eller 7-leddede sykliske amingruppen som eventuelt inneholder ett ytterligere heteroatom valgt fra gruppen som består av O, N og S;R9 representerer C1-C4-alkyl eller fenyl, hvori hvert C1-C4-alkyl eller fenyl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med R13;R10 representerer C1-C4-alkyl; ellerR9 og R10 sammen, i tilfellet av -N=(SO)R9R10-gruppe, representerer en 5- til 8-leddet heterosykloalkylgruppe;R11 representerer hydrogen, C1-C4-alkyl, -(CO)OR7, -(CO)NR7R8 eller CN;R12 representerer hydrogen eller C1-C4-alkyl;R13 representerer halogen, OH, -NR7R8, CN, NO2, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoksy, C1-C6-halogenalkoksy, C2-C6-alkenyl, C3-C6-sykloalkyl, -(CO)OR7 eller -(CO)NR7R8.5. Forbindelsen med generell formel (Ib) ifølge krav 4, derR1 representerer:hvori * indikerer festepunktet for gruppen med resten av molekylet; R2 representerer hydrogen, halogen, -NR7R8, CN, C1-C6-alkyl, C1-C4-alkoksy, 3- til 10-leddet heterosykloalkoksy, C2-C4-alkenyl, C3-C6-sykloalkyl, 3- til 10-leddet heterosykloalkyl, 4- til 10-leddet heterosykloalkenyl, fenyl, heteroaryl, -(CO)NR7R8, -(SO2)R9, -(SO)R9, -SR9, -N=(SO)R9R10, -(PO)(OR7)2, -(PO)(OR7)R10, -(PO)(R10)2, hvori hvert C1-C6-alkyl, C1-C4-alkoksy, C3-C6-sykloalkyl, 3- til 10-leddet heterosykloalkyl, fenyl eller heteroaryl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, medhalogen, OH, amino, -NR7R8,C1-C4-alkyl eventuelt substituert med hydroksyl eller fenyl, C1-C2-halogenalkyl, C1-C3-alkoksy, C3-C6-sykloalkyl, 3- til 6-leddet heterosykloalkyl, fenyl, -(CO)OR7, -(CO)NR7R8, -NR7(CO)R10, -NR8(CO)OR7, -(SO2)R9, -SR9, -NR7(SO2)R9, -((SO)=NR11)R10, -(PO)(OR7)2, -(PO)(OR7)R10, eller med en heteroarylgruppe;hvori hvert 4- til 10-leddede heterosykloalkenyl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med metyl;R4 representerer hydrogen eller metyl;R7, R8 representerer, uavhengig av hverandre, hydrogen, C1-C6-alkyl, C3-C6-sykloalkyl eller fenyl, idet fenylet eventuelt er substituert én eller flere ganger, med halogen;R9 representerer C1-C4-alkyl eller fenyl, hvori hvert C1-C4-alkyl eller fenyl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med R13;R10 representerer C1-C4-alkyl; ellerR9 og R10 sammen, i tilfellet av -N=(SO)R9R10-gruppe, representerer en 5- til 8-leddet heterosykloalkylgruppe;R11 representerer hydrogen, C1-C4-alkyl, -(CO)OR7, -(CO)NR7R8 eller CN;R13 representerer halogen, OH eller C1-C6-alkoksy.6. Forbindelsen med generell formel (Ib) ifølge kravene 4 eller 5, derR1 representerer:hvori * indikerer festepunktet for gruppen med resten av molekylet;R2 representerer hydrogen, klor,-amino, propylamino, dimetylamino, metyl(propyl)amino, metyl(2-metylpropyl)amino, 2,2-dimetylpropyl(metyl)amino, syklopropyl(metyl)amino, metyl(fenyl)amino, CN, metyl, etyl, propan-2-yl,3-metylbutan-2-yl, pentan-3-yl, heksan-2-yl, 3,3-dimetylbutan-2-yl, metoksy, etoksy, propoksy, butoksy, 2-metyl-propan-1-yloksy, propan-2-yloksy, (2-oksotetrahydrofuran-3-yl)oksy, propenyl, syklopropyl, sykloheksyl, azetidinyl,-pyrrolidinyl, 2-okso-1,3-oksazolidin-2-on, tetrahydro-2H-pyranyl, tetrahydro-2H-tiopyran-4-yl, piperidinyl, piperazinyl, morfolinyl, azepanyl, 2-okso-pyrrolidin-1-yl, 2-okso-piperidin-1-yl, 3-oksopiperazin-1-yl, 2-okso-1,3-oksazinan-3-yl, 1-oksidotetrahydro-2H-tiopyran-4-yl, 1,1-dioksidotetrahydro-2H-tiopyran-4-yl, 1,1-dioksido-1,2-tiazolidin-2-yl,5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl, 3-oksa-8-azabisyklo[3.2.1]okt-8-yl, 1,3,3-trimetyl-6-azabisyklo[3.2.1]okt-6-yl, (3aR,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl, (1S,4S)-2-oksa-5-azabisyklo[2.2.1]hept-5-yl, 1,1-dioksido-1-tia-6-azaspiro[3.3]hept-6-yl 2,5-dihydro-1H-pyrrol-1-yl, 3,6-dihydro-2H-pyran-4-yl, 1,2,5,6-tetrahydropyridin-3-yl, 1,2,3,6-tetrahydropyridin-4-yl, 3,6-dihydro-2H-tiopyran-4-yl, fenyl, 1,3-dihydro-2H-isoindol-2-yl, 3,4-dihydrokinolin-1(2H)-yl, 3,4-dihydroisokinolin-2(1H)-yl, pyrrolyl, pyrazolyl, tiofenyl, imidazolyl, oksazolyl, tiazolyl, triazolyl, oksadiazolyl, pyridinyl, pyrimidinyl, 2-okso-1,2-dihydropyridin-4-yl, indolyl, benzotiofenyl, kinolinyl, isokinolinyl, 1H-pyrrolo[2,3-b]pyridin-4-yl, 6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl, -(CO)NH2, metylsulfonyl, etylsulfonyl, propan-2-ylsulfonyl, fenylsulfonyl, metylsulfinyl, etylsulfinyl, propan-2-ylsulfinyl, fenylsulfinyl, metylsulfanyl, etylsulfanyl, propan-2-ylsulfanyl, fenylsulfanyl, -N=(SO)dimetyl, -N=(SO)dietyl,hvori * indikerer festepunktet for gruppen med resten av molekylet, -(PO)(O-metyl)2-(PO)(O-etyl)metyl, -(PO)(O-2-metylpropyl)metyl, -(PO)(O-etyl)2-metylpropyl, -(PO)dimetyl, -(PO)dietyl,hvori hvert metyl, etyl, propan-2-yl, 3-metylbutan-2-yl, pentan-3-yl, heksan-2-yl, 3,3-dimetylbutan-2-yl, metoksy, etoksy, propoksy, 2-metyl-propan-1-yloksy, butoksy, syklopropyl, sykloheksyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morfolinyl, 3-okso-piperazin-1-yl, fenyl, pyrrolyl, pyrazolyl, tiofenyl, imidazolyl, oksazolyl, tiazolyl, triazolyl, oksadiazolyl, pyridinyl, pyrimidinyl, indolyl, eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med fluor, klor, brom, OH, amino, -NH-syklopropyl, dimetylamino, metyl, etyl, propan-1-yl, propan-2-yl, 2-metylpropyl, tert-butyl, hydroksymetyl, 2-hydroksyetyl, 2-metyl-2-hydroksypropan-1-yl, 2-hydroksypropan-2-yl, benzyl, fluoretyl, difluormetyl, trifluormetyl, metoksy, etoksy, isopropoksy, metoksymetyl, syklopropyl, syklobutyl, tetrahydrofuranyl, tetrahydropyranyl, fenyl, -(CO)O-metyl, (CO)O-tert-butyl, -(CO)NH2, -(CO)NH-metyl, -(CO)NH-tert-butyl, -(CO)dimetylamino, -(CO)piperidin-1-yl, -(CO)NH-syklopropyl, -NH(CO)metyl, -NH(CO)O-tert-butyl, metylsulfonyl, etylsulfonyl, propan-2-ylsulfonyl, fenylsulfonyl, metylsulfanyl, -(SO2)NR7R8, NH(SO2)metyl,-((SO)=NH)metyl, -((SO)=NH)etyl, -((SO)=NH)propan-2-yl, -((SO)=N-metyl)metyl, -((SO)=N-(CO)O-etyl)metyl, -((SO)=N-(CN))metyl, -((SO)=N-(CO)NH-etyl)metyl, -(PO)(O-metyl)2, -(PO)(OH)(O-metyl) eller med furanyl, pyrazolyl,hvori hvert 1,2,5,6-tetrahydropyridin-3-yl, 1,2,3,6-tetrahydropyridin-4-yl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med metyl;R4 representerer hydrogen eller metyl.7. Forbindelsen med generell formel (Ib) ifølge ett av kravene 4 til 6, der R1 representerer:hvori * indikerer festepunktet for gruppen med resten av molekylet;R2 representerer 2,2-dimetylpropyl(metyl)amino, syklopropyl(metyl)amino, metyl(fenyl)amino, 3-metylbutan-2-yl, syklopropyl, tetrahydro-2H-pyranyl, tetrahydro-2H-tiopyran-4-yl, piperidinyl, piperazinyl, 5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl, 3,6-dihydro-2H-tiopyran-4-yl, fenyl, pyrrolyl, pyrazolyl, tiofenyl, imidazolyl, oksazolyl, tiazolyl, pyridinyl, 1H-pyrrolo[2,3-b]pyridin-4-yl eller 6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl,hvori hvert 3-metylbutan-2-yl, syklopropyl, piperidinyl, piperazinyl, fenyl, pyrrolyl, pyrazolyl, tiofenyl, imidazolyl, oksazolyl, tiazolyl eller pyridinyl eventuelt er substituert, én eller to eller tre ganger, uavhengig av hverandre, med fluor, klor, OH, amino, metyl, etyl, propan-1-yl, propan-2-yl, tert-butyl, hydroksymetyl, benzyl, fluoretyl, trifluormetyl, metoksy, syklopropyl, -(CO)O-metyl, metylsulfonyl, metylsulfanyl, -((SO)=NH)metyl; R4 representerer metyl.8. Forbindelsen med generell formel (Ib) ifølge ett av kravene 4 til 7, derR1 representerer:hvori * indikerer festepunktet for gruppen med resten av molekylet;R2 representerer tetrahydro-2H-tiopyran-4-yl, piperidinyl, 5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl, fenyl, pyrrolyl, pyrazolyl, oksazolyl, pyridinyl eller 6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl, hvori hvert piperidinyl, fenyl, pyrrolyl, pyrazolyl, oksazolyl eller pyridinyl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, med fluor, amino, metyl, etyl, propan-2-yl, hydroksymetyl, metoksy, syklopropyl, metylsulfonyl, metylsulfanyl, -((SO)=NH)metyl;R4 representerer metyl.9. Forbindelsen med generell formel (Ib) ifølge ett av kravene 4 til 7, derR1 representerer:hvori * indikerer festepunktet for gruppen med resten av molekylet;R2 representerer 2,2-dimetylpropyl(metyl)amino, syklopropyl(metyl)amino, metyl(fenyl)amino, 3-metylbutan-2-yl, syklopropyl, tetrahydro-2H-pyranyl, tetrahydro-2H-tiopyran-4-yl, piperidin-4-yl, piperazin-1-yl, 5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl, 3,6-dihydro-2H-tiopyran-4-yl, fenyl, pyrrol-2-yl, 1H-pyrazol-5-yl, 1H-pyrazol-4-yl, tiofen-2-yl, tiofen-3-yl, 1H-imidazol-5-yl, 1,2-oksazol-5-yl, 1,3-tiazol-5-yl, pyridin-3-yl, pyridin-4-yl, 1H-pyrrolo[2,3-b]pyridin-4-yl eller 6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl,hvori hvert 3-metylbutan-2-yl, syklopropyl, piperidin-4-yl, piperazin-1-yl, fenyl, pyrrol-2-yl, 1H-pyrazol-5-yl, 1H-pyrazol-4-yl, tiofen-2-yl, tiofen-3-yl, 1H-imidazol-5-yl,1,2-oksazol-5-yl, 1,3-tiazol-5-yl, pyridin-3-yl eller pyridin-4-yl eventuelt er substituert, én eller flere ganger, uavhengig av hverandre, medfluor, klor, OH, amino, metyl, etyl, propan-1-yl, propan-2-yl, tert-butyl, hydoksymetyl, benzyl, 2-fluoretyl, trifluormetyl, metoksy, syklopropyl, -(CO)O-metyl, metylsulfonyl, metylsulfanyl eller -((SO)=NH)metyl; R4 representerer metyl.10. Forbindelsen med generell formel (I) eller (Ib) ifølge ett av kravene 1 til 9, som er 2-[(3R)-3-metylmorfolin-4-yl]-4-(1-metyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naftyridin.11. Forbindelsen med generell formel (I) eller (Ib) ifølge ett av kravene 1 til 10, for anvendelse ved behandlingen eller profylaksen av en sykdom.12. Farmasøytisk sammensetning som omfatter forbindelsen med generell formel (I) eller (Ib) ifølge ett av kravene 1 til 10 og én eller flere farmasøytisk akseptable eksipienser.13. Farmasøytisk sammensetning ifølge krav 12 for anvendelse ved behandling eller profylakse av en hyperproliferativ sykdom.14. Farmasøytisk kombinasjon som omfatter:- én eller flere aktive ingrediens(er) valgt fra en forbindelse med generell formel (I) eller (Ib) ifølge ett av kravene 1 til 10, og- én eller flere aktive ingrediens(er) valgt fra anti-hyperproliferative, cytostatiske eller cytotoksiske stoffer for behandling av kreft.15. Forbindelse med generell formel 8der R1, R3 og R4 er som definert for forbindelsen med generell formel (I) eller (Ib) ifølge ett av kravene 1 til 10.
Hva betyr A1, B, B1, C osv? info

Klasser info chevron_right

Innehaver(e) info chevron_right

Innehaver i EP:
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178 13353 Berlin DE

Oppfinner(e) info chevron_right

WORTMANN, Lars
Kastanienallee 103 10435 Berlin DE
LÜCKING, Ulrich
Paula-Fürst-Strasse 2 10317 Berlin DE
LEFRANC, Julien
Wallstr. 26 10179 Berlin DE
BRIEM, Hans
Emser Strasse 3 10719 Berlin DE
KOPPITZ, Marcus
Elsenbruchstrasse 34A 13467 Berlin DE
EIS, Knut
Fichtenweg 1 13587 Berlin DE
VON NUSSBAUM, Franz
Kreuzritterstrasse 3 DE-13465 Berlin DE
BADER, Benjamin
Hillmannstrasse 14 13467 Berlin DE
WENGNER, Antje Margret
Borkumstrasse 12 e 13189 Berlin DE
SIEMEISTER, Gerhard
Reimerswalder Steig 26 13503 Berlin DE
BONE, Wilhelm
Drewitzer Strasse 46 13467 Berlin DE
LIENAU, Philip
Jahnstrasse 13 10967 Berlin DE
GRUDZINSKA-GOEBEL, Joanna
An den Eldenaer Höfen 37 10247 Berlin DE
MOOSMAYER, Dieter
Wöhlertstrasse 11 10115 Berlin DE
EBERSPÄCHER, Uwe
Zerndorfer Weg 59 13465 Berlin DE
SCHICK, Hans
"-" deceased DE

Fullmektig info chevron_right

Fullmektig i Norge:
ZACCO NORWAY AS
Postboks 488 0213 OSLO NO ( OSLO kommune, Oslo fylke )

Org.nummer: 982702887
Din referanse: V6211NO00
  • Foretaksnavn:
  • Foretaksform:
  • Næring:
  • Forretningsadresse:
     

Kilde: Brønnøysundregistrene
Fullmektig i EP:
BIP Patents
c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50 40789 Monheim am Rhein DE

Prioritet info chevron_right

2014.08.04, EP 14179692

2015.03.17, EP 15159342

Anførte dokumenter info chevron_right

WO-A1-2011/163527 (B1)

WO-A1-2010/073034 (B1)

Sakshistorikk info chevron_right

Statushistorie

Liste over statusendringer i sakshistorikk
Hovedstatus Beslutningsdato, detaljstatus
Patent opphørt Ikke betalt årsavgift
EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
EP under behandling Forespørsel om å gjøre EP patent gyldig er mottatt

Korrespondanse

expand_more file_download  
Liste over sakshistorikk og korrespondanse
Dato Type korrespondanse Journal beskrivelse
Utgående EP Opphørt for ikke betalt årsavgift (3206)
11-01 Via Altinn-sending EP Opphørt for ikke betalt årsavgift (3206)
Utgående EP Påminnelse om ikke betalt årsavgift (3331) (PTEP3177619)
10-01 Via Altinn-sending EP Påminnelse om ikke betalt årsavgift (3331) (PTEP3177619)
Innkommende EP Publiseringsdokument fra EPO
09-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
08-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
07-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
06-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
05-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Registreringsbrev (3210)
04-01 Brev UT EP Registreringsbrev (3210)
Utgående EP Batch Varsel om betaling av første årsavgift (3319)
03-01 Via Altinn-sending EP Batch Varsel om betaling av første årsavgift (3319)
Innkommende, AR273240844 Søknadsskjema Patent
01-01 Søknadsskjema Patent Søknadsskjema Patent
01-02 EP oversettelse EP krav
01-03 Fullmakt Fullmakt
Innkommende EP Publiseringsdokument fra EPO
02-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Informasjon om ikke tilgjengelige dokumenter

Betaling info chevron_right

Til betaling:

Betalingshistorikk:

Liste av betalinger
Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status
Årsavgift 9. avg. år (EP) 2023.08.09 2850 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 8. avg. år (EP) 2022.08.09 2550 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 7. avg. år (EP) 2021.08.10 2200 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 6. avg. år (EP) 2020.08.11 2000 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 5. avg. år (EP) 2019.08.12 1650 CPA GLOBAL LIMITED Betalt og godkjent
31812230 expand_more 2018.08.16 5500 TANDBERG INNOVATION AS Betalt
Årsavgift 4. avg. år (EP) 2018.08.09 1350 CPA GLOBAL LIMITED Betalt og godkjent
Denne oversikten kan mangle informasjon, spesielt for eldre saker, om tilbakebetaling, internasjonale varemerker og internasjonale design.

Publikasjon(er) info chevron_right

Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter)

Oversettelse av europeisk patentskrift
Allment tilgjengelig patentsøknad
Norsk Patenttidende - ved meddelelse
Nye digitale Norske Tidende, nyhet om tjenesten ved lansering
Om Norske Tidende
Hva betyr A1, B, B1, C osv? info
Kapitler uten data er fjernet. Melding opprettet: 02.05.2025 05:59:49